Eli Lilly and Novo Nordisk each beat second-quarter estimates and raised full-year guidance this week. The equity market's response was split: Lilly shares climbed roughly 7%, while Novo closed approximately 6% lower. That gap reflects a structural divergence now visible in prescription data, pipeline trajectories, and manufacturing commitments—one that is repricing the entire obesity-drug sector.
The Numbers Behind the Divide
Lilly posted $22.97 billion in Q2 revenue, up 48% year-over-year. Mounjaro, Zepbound and the recently launched oral Foundayo produced approximately $14.97 billion—about 65% of the company's total sales. Volume surged 60%, partially offset by a 13% decline in realized prices. Lilly raised its 2026 revenue guidance to $85–87 billion and adjusted EPS to $35.50–$36.50.
Novo reported DKK78.49 billion, with adjusted growth of 7% at constant exchange rates. Its revised guidance range still permits adjusted sales and operating profit to decline by as much as 6% for the full year. The company also recorded DKK6.3 billion of impairments, DKK4 billion of which were tied to the discontinued monlunabant program.
Lilly's market capitalization now stands at roughly $1.07 trillion—approximately 5.25 times Novo's $203 billion. That multiple exceeds any reasonable ratio of their current pharmaceutical revenues and reflects investor conviction about future market share, pipeline productivity, and manufacturing execution.
Prescription Share Has Tipped Decisively
Late-July IQVIA data cited by Citi analysts placed Zepbound at 58.9% of tracked branded U.S. obesity prescriptions, with injectable Wegovy at 40.6%. Weekly scripts ran at approximately 710,000 for Zepbound and 495,500 for injectable Wegovy. The two products together accounted for 99.5% of the tracked branded market—confirmation that commercial obesity remains a two-company contest.
Novo retains a meaningful lead in the oral segment. The company reported over 265,000 weekly Wegovy-pill prescriptions and more than five million cumulative scripts since launch. Lilly's Foundayo registered only about 29,400 weekly prescriptions. Oral obesity is a separate race, and Novo is winning it by a wide margin for now.
The Pipeline Gap Has Widened
Lilly's retatrutide produced average weight loss of 28.3% at 80 weeks in its Phase 3 TRIUMPH-1 trial, reaching roughly 30.3% at 104 weeks in the extension analysis. About 45% of participants on the highest dose lost at least 30% of body weight. Lilly has completed the principal Phase 3 package and plans a regulatory filing in Q1 2027.
Novo's near-term counterweight, CagriSema—combining semaglutide with the amylin analogue cagrilintide—suffered a credibility wound when REDEFINE 4 failed to establish non-inferiority against tirzepatide. A separate diabetes trial also missed its HbA1c non-inferiority target against tirzepatide. Novo has later-stage assets, including injectable and oral zenagamtide (formerly amycretin) advancing into Phase 3, plus higher-dose Wegovy 7.2mg and an early triple-agonist program. An FDA decision on CagriSema is expected in Q4 2026.
Competitors are credible but distant. Roche's enicepatide has shown 22.5% placebo-adjusted weight loss at 48 weeks with no apparent plateau and entered Phase 3. Amgen's monthly-dosed MariTide produced around 20% loss at 52 weeks. Viking has fully enrolled Phase 3 trials but lacks safety, durability, and manufacturing data. Pfizer is running ten Phase 3 programs across a portfolio of oral, injectable, and monthly-maintenance candidates. None of these companies is likely to build material commercial share before 2028.
The Metric That Actually Determines the Winner
Lilly's 13% realized-price decline alongside 60% volume growth and a gross margin of 85.8% reveals the real economic logic now governing the sector. The category is transitioning away from scarcity pricing—when constrained supply allowed premium realization—toward throughput economics: lower net prices multiplied by a vastly larger treated population, longer treatment duration, and multiple indications.
Under this model, the winning company acquires patients cheaply through oral products and accessible pricing ($149/month for Foundayo, $299–449 for Zepbound depending on dose), retains them across formulations and escalation pathways, manufactures at scale with owned capacity (Lilly has committed another $4.5 billion to Indiana plants), and accumulates the outcomes data needed to secure durable reimbursement—including through the Medicare GLP-1 Bridge program, which began July 1, 2026 with eligible beneficiaries paying about $50 per month.
The scarce resource has shifted. Supply constraints are easing. Persistent patients—individuals who stay on therapy at months 6, 12, and 24—have become the variable that determines lifetime gross profit. A drug with 20% weight loss, easier dosing, and lower discontinuation rates can generate more economic value per patient than a 28% product with poor tolerability and high dropout. The most dangerous metric in the industry remains "prescriptions written," because the economically relevant funnel runs from eligibility through approval, dispensing, titration, retention, renewal, and measurable clinical improvement.
Lilly can now sequence patients from injectable tirzepatide to oral Foundayo to retatrutide, creating an escalation architecture within a single manufacturer's portfolio. Novo must defend semaglutide while proving that its next-generation molecules can restore competitive parity. Every other company must demonstrate a specific friction advantage—monthly dosing, superior tolerability, lean-mass preservation, or liver-disease benefit—because another weekly injectable with comparable efficacy will lack pricing power in a market Lilly is defining by throughput, not scarcity.
not investment advice
Sources: https://investor.lilly.com/events/event-details/q2-2026-earnings-call